Aug. 8 at 11:19 PM
$VXRT Challenge Accepted (4 of 4)
WHAT DOES DELAWARE APPRAISAL ACTUALLY VALUE?
§262(h) instructs the court to determine fair value while:
“excluding any element of value arising from the accomplishment or expectation of the merger”
and considering:
“all relevant factors.”
In plain English:
The court generally tries to determine the target’s standalone going-concern value immediately before the merger.
Existing pipeline prospects CAN matter.
Legitimate future business opportunities CAN matter.
But merger-created value and buyer-specific synergies are excluded.
THIS IS IMPORTANT FOR VXRT.
Suppose Vaxart already had:
* successful Phase 3 data
* a near-approval norovirus program
* a large royalty stream
* commercially established platform economics
A buyer obviously could not sensibly argue that none of those things have value simply because VXRT happened to trade cheaply.
Delaware appraisal is NOT automatically chained to the stock quote.
So the people saying:
“Market price isn’t necessarily true value”
have a legitimate point.
WHERE THEY GO OFF THE RAILS is what comes next.
Delaware does NOT tell a court to assume:
100% clinical success
+
100% regulatory success
+
100% commercial success
+
maximum market penetration
+
maximum royalties
+
all platform optionality
+
all buyer synergies
and then force the acquirer to pay the sum.
Future opportunities are uncertain.
They are probability-weighted.
They are discounted to present value.
And speculative merger-specific value is excluded.
That is ordinary rNPV valuation reality.
DELAWARE SUPREME COURT CASE LAW IS ESPECIALLY DAMAGING TO THE “TRUE VALUE = HUGE BUYOUT” THEORY.
In DFC, Dell and Aruba, Delaware made clear there is no automatic rule that deal price always equals fair value.
BUT:
A well-run arm’s-length sale process and competitive market can provide extremely powerful evidence of fair value.
In other words, Delaware courts often take ACTUAL MARKET EVIDENCE very seriously.
They do not automatically substitute an enormous theoretical DCF because somebody thinks management undersold the potential.
AND THE JARDEN CASE IS ALMOST THE PERFECT RESPONSE TO THIS ARGUMENT.
Jarden was acquired for:
$59.21/share.
Shareholders sought appraisal.
The Delaware Court of Chancery determined FAIR VALUE was only:
$48.31/share.
The Delaware Supreme Court AFFIRMED it.
Read that again:
ACQUISITION PRICE:
$59.21
DELAWARE “FAIR VALUE”:
$48.31
So appraisal can actually determine that standalone fair value is BELOW the merger consideration.
The Delaware Supreme Court also explicitly rejected the idea that “fair value” means the HIGHEST POSSIBLE PRICE a company could obtain.
That alone should end the claim that Delaware law automatically ratchets acquisition values upward.
Why can deal price exceed appraisal fair value?
Because an acquirer may rationally pay for:
* combination synergies
* strategic advantages
* cost savings
* control
* competitive positioning
Those merger-specific benefits are not automatically part of statutory standalone fair value.
This is exactly why it is important to distinguish:
STANDALONE VALUE
from
CONTROL / STRATEGIC TRANSACTION VALUE.
ANOTHER IMPORTANT MISUNDERSTANDING:
APPRAISAL DOES NOT AUTOMATICALLY RESET THE MERGER PRICE FOR EVERY SHAREHOLDER.
It is generally a post-closing statutory remedy for qualifying shareholders who properly dissent and perfect appraisal rights.
Those holders ask the court to determine what THEIR shares were worth under §262.
That is completely different from:
“Before Sanofi buys Vaxart, Delaware requires it to offer everybody judicial fair value.”
It does not.
SO WHAT WOULD DELAWARE LAW ACTUALLY MEAN IN A VXRT SALE?
It could matter if:
* the board ran a conflicted or unreasonable sales process
* management favored one buyer improperly
* competing higher bids were ignored
* legitimate existing pipeline value was disregarded
* shareholders properly pursued fiduciary/appraisal remedies
It helps protect shareholders.
GOOD.
But Delaware incorporation is not some secret valuation cheat code.
It cannot turn
$0.55 into
$45.
THE BETTER WAY TO THINK ABOUT ACQUISITION VALUE IS:
Standalone risk-adjusted asset value
Control premium
Competitive tension between bidders
A negotiated share of strategic synergies
Value of removing financing/development risk
Platform/strategic optionality
How badly the buyer wants to prevent somebody else from owning it
=
Potential transaction value.
THAT is how you get a major premium.
Not:
“Delaware law says true value, therefore
$45.”
NOW DO A REVERSE VALUATION ON THE
$45 CLAIM.
Assume Vaxart eventually reaches ~300M diluted shares.
$1 =
$300M equity value
$2 =
$600M
$3 =
$900M
$5 =
$1.5B
$10 =
$3B
$20 =
$6B
$45 =
$13.5 BILLION
So the intellectually correct question is NOT:
“Can a
$0.55 stock be bought for
$45?”
Of course a stock can theoretically rise by any percentage.
The correct question is:
“WHAT FUNDAMENTAL ASSUMPTIONS ARE REQUIRED TO JUSTIFY A
$13.5 BILLION CONTROL VALUATION?”
That requires reverse-engineering:
* probability of clinical success
* probability of regulatory approval
* peak sales
* market penetration
* pricing
* duration of exclusivity
* royalty economics
* value of additional indications
* platform value
* strategic synergies
* required return/cost of capital
Today I cannot construct a defensible rNPV anywhere near
$13.5B without assigning extremely aggressive probabilities and commercial values to multiple outcomes that have NOT yet been demonstrated.
That is the fundamental problem with the
$45 argument.
Could Vaxart theoretically someday become worth
$13.5B?
Sure.
If the technology eventually produces multiple commercially successful vaccines, enormous royalties and a broadly validated oral vaccine platform, almost anything is possible.
But nothing currently known justifies
$13.5B TODAY.
And one successful Phase 2b would not automatically justify it either.
Delaware law certainly does not manufacture the missing
$12B+ of value.
SCIENCE, REGULATORY SUCCESS AND COMMERCIAL EXECUTION would have to do that.
WHEN WOULD I ACTUALLY WANT VAXART SOLD?
Personally, not today for
$1–
$1.50 unless management privately had strong reasons to doubt the science.
Today Vaxart negotiates from weakness.
The much better theoretical sequence is:
Successful COVID P2b
→
Sanofi elects
→
Vaxart receives
$50M
→
COVID development costs transfer
→
Norovirus gets partnered/de-risked
THEN negotiate.
Imagine Vaxart being able to tell a buyer:
“We have cash.
Our largest development program is being funded by Sanofi.
We have milestone/royalty economics.
Norovirus is independently validated and financed.
We don’t NEED to sell.”
THAT is negotiating leverage.
That is how sellers capture more of the CONTROL PREMIUM / SYNERGY VALUE.
Not by threatening the buyer with Delaware appraisal law.
KEY RISKS I WOULD PUT ON AN INVESTMENT-COMMITTEE PAGE:
VERY HIGH:
Financing/dilution
VERY HIGH:
COVID efficacy/event count
HIGH:
Sanofi declines election
MEDIUM-HIGH:
Further BARDA modifications
MEDIUM-HIGH:
Norovirus challenge results don’t translate to field efficacy
HIGH:
Norovirus funding
MEDIUM:
Manufacturing/scale-up
MEDIUM:
Ad5/vector/repeat-use questions
MEDIUM:
IP duration/defensibility
HIGH:
OTCQX/liquidity
HIGH:
Ultimate commercial COVID market
This is why VXRT remains speculative despite attractive expected value.
WHAT WOULD INCREASE MY VALUATION THE MOST?
#1 — CLEAR PHASE 2B COVID EFFICACY
Nothing else is close.
This raises clinical PoS and therefore the rNPV of the entire downstream Sanofi economics.
#2 — SANOFI ELECTS TO PROCEED
Science + financing + third-party validation + lower future capital requirements.
#3 — MEANINGFUL NOROVIRUS PARTNERSHIP
Could dramatically reduce financing risk and establish independent second-program validation.
#4 — STRONG NEXT-GEN NOROVIRUS CLINICAL RESULTS
Especially evidence that improved immunogenicity translates into actual protection.
#5 — CLEAR FDA PATH FOR COVID PHASE 3/APPROVAL
Regulatory clarity reduces both timeline risk and capital uncertainty.
#6 — REPEAT EFFICACY ACROSS MULTIPLE DISEASES
That is what transforms residual PLATFORM OPTION VALUE into something that deserves a genuine platform multiple.
BOTTOM LINE AT ~
$0.55:
I am constructive/bullish on the RISK/REWARD.
Current fundamental value:
~
$0.80–
$1.05
My central NAV:
~
$0.90
12–18 month scenario-weighted expected NAV:
~
$1.05–
$1.15
Failure:
~
$0.15–
$0.30
Strong COVID + Sanofi:
~
$1.55–
$2.60
COVID + meaningful noro validation:
~
$2.35–
$4
Later validated platform:
~
$5–
$10+
Realistic buyout after substantial de-risking:
Broadly ~
$650M–
$1.5B / ~
$2.30–
$5.20 depending on exactly what has happened.
That is what I find compelling about VXRT.
At
$0.55, you DON’T need a
$20 or
$45 buyout fantasy to make the risk/reward potentially attractive.
You need some combination of:
COVID success
+
Sanofi participation
+
norovirus advancement
+
reasonable financing.
If those happen, substantial upside is supportable under an rNPV/SOTP framework without inventing valuations.
If they don’t, the downside is very real.
My framework therefore isn’t:
“VXRT WILL BE
$X.”
It is a LIVING VALUATION MODEL.
Every:
BARDA modification
clinical result
Sanofi development
norovirus publication
partnership
financing
share issuance
regulatory decision
changes PoS, expected future cash flows, dilution assumptions and therefore NAV.
Right now my working SOTP/rNPV is roughly
$0.90 against a ~
$0.55 market price.
That makes VXRT interesting to me.
But it remains a high-risk, asymmetric biotech investment — not a guaranteed ticket to a
$13B buyout.
And Delaware law does not change that.
